REGENXBIO (RGNX) Competitors $12.30 +1.05 (+9.33%) Closing price 04:00 PM EasternExtended Trading$12.04 -0.26 (-2.11%) As of 05:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RGNX vs. OCUL, ANIP, VERA, TWST, DYN, APGE, COGT, TLRY, ABCL, and IMCRShould you be buying REGENXBIO stock or one of its competitors? The main competitors of REGENXBIO include Ocular Therapeutix (OCUL), ANI Pharmaceuticals (ANIP), Vera Therapeutics (VERA), Twist Bioscience (TWST), Dyne Therapeutics (DYN), Apogee Therapeutics (APGE), Cogent Biosciences (COGT), Tilray Brands (TLRY), AbCellera Biologics (ABCL), and Immunocore (IMCR). These companies are all part of the "pharmaceutical products" industry. REGENXBIO vs. Its Competitors Ocular Therapeutix ANI Pharmaceuticals Vera Therapeutics Twist Bioscience Dyne Therapeutics Apogee Therapeutics Cogent Biosciences Tilray Brands AbCellera Biologics Immunocore Ocular Therapeutix (NASDAQ:OCUL) and REGENXBIO (NASDAQ:RGNX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, media sentiment, earnings, valuation, risk and analyst recommendations. Does the media prefer OCUL or RGNX? In the previous week, Ocular Therapeutix had 7 more articles in the media than REGENXBIO. MarketBeat recorded 19 mentions for Ocular Therapeutix and 12 mentions for REGENXBIO. Ocular Therapeutix's average media sentiment score of 0.74 beat REGENXBIO's score of 0.41 indicating that Ocular Therapeutix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocular Therapeutix 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive REGENXBIO 2 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility & risk, OCUL or RGNX? Ocular Therapeutix has a beta of 1.45, suggesting that its stock price is 45% more volatile than the S&P 500. Comparatively, REGENXBIO has a beta of 1.17, suggesting that its stock price is 17% more volatile than the S&P 500. Is OCUL or RGNX more profitable? REGENXBIO has a net margin of -112.70% compared to Ocular Therapeutix's net margin of -382.51%. REGENXBIO's return on equity of -66.95% beat Ocular Therapeutix's return on equity.Company Net Margins Return on Equity Return on Assets Ocular Therapeutix-382.51% -71.92% -49.36% REGENXBIO -112.70%-66.95%-34.14% Which has better earnings & valuation, OCUL or RGNX? Ocular Therapeutix has higher earnings, but lower revenue than REGENXBIO. Ocular Therapeutix is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOcular Therapeutix$63.72M32.60-$193.51M-$1.28-9.33REGENXBIO$83.33M7.46-$227.10M-$3.44-3.58 Do insiders and institutionals believe in OCUL or RGNX? 59.2% of Ocular Therapeutix shares are held by institutional investors. Comparatively, 88.1% of REGENXBIO shares are held by institutional investors. 2.3% of Ocular Therapeutix shares are held by insiders. Comparatively, 12.8% of REGENXBIO shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Do analysts rate OCUL or RGNX? Ocular Therapeutix presently has a consensus price target of $22.63, indicating a potential upside of 89.49%. REGENXBIO has a consensus price target of $28.38, indicating a potential upside of 130.69%. Given REGENXBIO's higher probable upside, analysts plainly believe REGENXBIO is more favorable than Ocular Therapeutix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ocular Therapeutix 1 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.75REGENXBIO 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57 SummaryOcular Therapeutix and REGENXBIO tied by winning 8 of the 16 factors compared between the two stocks. Get REGENXBIO News Delivered to You Automatically Sign up to receive the latest news and ratings for RGNX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RGNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RGNX vs. The Competition Export to ExcelMetricREGENXBIOMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$621.27M$3.40B$6.05B$10.51BDividend YieldN/A2.30%5.73%4.80%P/E Ratio-3.5822.9285.3627.35Price / Sales7.46268.92516.10196.40Price / CashN/A46.9537.5761.53Price / Book2.3510.5512.426.82Net Income-$227.10M-$52.58M$3.32B$276.80M7 Day Performance0.65%1.09%0.97%0.26%1 Month Performance35.31%16.09%10.70%8.29%1 Year Performance19.42%18.41%76.19%35.59% REGENXBIO Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RGNXREGENXBIO4.392 of 5 stars$12.30+9.3%$28.38+130.7%+10.3%$621.27M$83.33M-3.58370OCULOcular Therapeutix3.9527 of 5 stars$10.97-3.9%$22.13+101.7%+7.4%$1.99B$56.66M-8.57230ANIPANI Pharmaceuticals3.9363 of 5 stars$92.06+2.7%$97.29+5.7%+51.7%$1.95B$614.38M-119.56600News CoverageVERAVera Therapeutics2.3255 of 5 stars$30.94+2.7%$63.00+103.6%-28.2%$1.92BN/A-8.6440TWSTTwist Bioscience3.8013 of 5 stars$31.85+2.5%$48.90+53.5%-34.5%$1.88B$312.97M-21.97990DYNDyne Therapeutics3.4226 of 5 stars$12.65-3.1%$34.07+169.3%-53.6%$1.86BN/A-3.28100Analyst UpgradeAPGEApogee Therapeutics3.0932 of 5 stars$39.82-0.2%$92.63+132.6%-6.2%$1.84BN/A-9.6491COGTCogent Biosciences2.0045 of 5 stars$15.90+0.9%$20.00+25.8%+36.4%$1.79BN/A-8.9380High Trading VolumeTLRYTilray Brands2.3473 of 5 stars$1.58-2.5%$1.94+22.6%+0.6%$1.78B$821.31M-0.682,842Earnings ReportOptions VolumeGap UpABCLAbCellera Biologics2.2514 of 5 stars$5.87-0.5%$8.00+36.3%+123.0%$1.76B$28.83M-10.67500IMCRImmunocore2.2929 of 5 stars$34.01-0.6%$56.89+67.3%-1.5%$1.72B$310.20M-85.03320 Related Companies and Tools Related Companies OCUL Alternatives ANIP Alternatives VERA Alternatives TWST Alternatives DYN Alternatives APGE Alternatives COGT Alternatives TLRY Alternatives ABCL Alternatives IMCR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RGNX) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding REGENXBIO Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share REGENXBIO With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
